(2023). Proton pump inhibitors and the risk of inflammatory bowel disease: population-based cohort study. Gut. http://doi.org/10.1136/gutjnl-2022-328866
. R. Pradhan
First name
R.
Last name
Pradhan
(2022). Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study. Bmj, 379, e071380. http://doi.org/10.1136/bmj-2022-071380
. (2022). Incretin-Based Drugs and the Risk of Acute Liver Injury Among Patients With Type 2 Diabetes. Diabetes Care. http://doi.org/10.2337/dc22-0712
. (2022). Glucagon-Like Peptide-1 Receptor Agonists and Risk of Anaphylactic Reaction Among Patients With Type 2 Diabetes: Multisite Population-Based Cohort Study. Am J Epidemiol. http://doi.org/10.1093/aje/kwac021
. (2022). Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Nonalcoholic Fatty Liver Disease Among Patients With Type 2 Diabetes. Diabetes Care. http://doi.org/10.2337/dc21-1953
. (2022). Long-Term patterns of cancer incidence among patients with and without type 2 diabetes in the United Kingdom. Diabetes Res Clin Pract, 185, 109229. http://doi.org/10.1016/j.diabres.2022.109229
. (2019). The Use of Long-Acting Insulin Analogs and the Risk of Colorectal Cancer Among Patients with Type 2 Diabetes: A Population-Based Cohort Study. Drug Saf. http://doi.org/10.1007/s40264-019-00892-5
. (2021). Defining Clinically-Relevant Target Populations Using Real-World Data to Guide the Design of Representative Antidiabetic Drug Trials. Clin Pharmacol Ther. http://doi.org/10.1002/cpt.2213
.